Sun Pharma launches phenobarbital sodium injection in US

Sun Pharma recently launched its phenobarbital sodium injection, Sezaby, for treatment of neo-natal seizures in the US.

Sezaby is the first and only product approved by the United States Food and Drug Administration (USFDA) for the treatment of neo-natal seizures in term and pre-term infants, Sun Pharma said in a regulatory filing.

It is a benzyl alcohol-free and propylene glycol-free formulation of phenobarbital sodium powder for injection.

“The launch of Sezaby is an exciting addition to our growing portfolio of specialty branded products in the US,” Abhay Gandhi, CEO, North America, Sun Pharma, said.

He further said, “As the first and only FDA-approved product for the treatment of seizures in term and pre-term infants, Sezaby has the potential to make a meaningful difference in the lives of patients and their families, and we are proud to be able to provide physicians with this new treatment option.”

Sun Pharma’s Sezaby was granted ‘orphan drug’ designation by the USFDA for the treatment of neo-natal seizures.

Edits by EP News Bureau